Skip to content
ELIOS logo in London skyline

Elios Vision announces registration of ELIOS in the United Kingdom

ELIOS is now registered for use in the United Kingdom. ELIOS is an innovative technology used to treat glaucoma at the same time as cataract surgery. It does not require an implant and provides long-lasting results that may free patients and their doctors from the demands of drop therapy.1 ELIOS technology uses excimer laser energy to create microscopic openings in the trabecular meshwork (TM) to re-establish the natural flow of aqueous.

“The ELIOS procedure is filling the gap for patients who don’t need an aggressive surgical approach, but are not doing well with drop therapy or would be much better off reducing their drop regimen,” says Ike Ahmed, MD, a Canada-based ophthalmologist and world-renowned glaucoma expert. “ELIOS has been particularly impactful for cataract surgery in my practice. It just makes sense to combine ELIOS with cataract surgery when you’re already going into the eye.”

As the leading cause of blindness worldwide, glaucoma is a devastating disease. ELIOS provides an opportunity to address the most common cause of blindness during the most commonly performed surgical procedure in the world with a safety profile similar to cataract surgery.2

“Multiple clinical studies across Europe have demonstrated that ELIOS has a strong efficacy and safety profile, with significant advantages over other forms of microinvasive glaucoma surgery (MIGS),” said Elliot Friedman, Chief Executive Officer of Elios Vision.

One such advantage ELIOS technology has over other forms of MIGS is that it is implant free, meaning fewer decisions for surgeons and less potential post-op trauma for patients. Furthermore, ELIOS’ use of an excimer laser lowers the surgery’s complexity, both intra- and post-op, as it avoids thermal or mechanical trauma.1 The ten microchannels this technology creates have proven to be effective and long-lasting for up to eight years.2

“Cataract surgery is an opportune time to improve glaucoma control and especially to reduce the medication burden in those on chronic therapy. ELIOS’ excimer laser technology removes TM tissue with minimal surgical trauma, minimizing the healing response and avoiding the need to place an implant. This makes ELIOS a very attractive option at the time of cataract surgery,” says Prof Keith Barton, Consultant Ophthalmologist, Moorfields Eye Hospital, London.

Elios Vision was founded in partnership with MLase, a world leader in excimer laser technology and now has a team dedicated to driving forward the global clinical and regulatory strategy for the novel excimer laser platform and procedure.

Matt Coleman

  1. Töteberg-Harms et al. BMC Ophthalmology 2013
  2. Riesen M, Funk J, Töteberg-Harms M. “Long-term treatment success and safety of combined phacoemulsification plus excimer laser trabeculostomy: an 8-year follow-up study”. Graefes Arch Clin Exp Ophthalmol. 2022 Jan 16.

Share This Story

Latest News

Join Us for a Symposium During EGS in Dublin

Elios Vision will be hosting a symposium, “Excimer lasers in glaucoma: More than meets the eye,” during the EGS congress in Dublin.

Video: Combined Phacoemulsification and ELIOS for Medication Reduction

Dr. Antonio Moreno-Valladares discusses a recent study of medication reduction outcomes for the ELIOS procedure combined with phacoemulsification.

Elios Vision announces collaboration with the International Glaucoma Surgical Registry

Elios Vision will be collaborating with the ISGR, an open-access tool which enables surgeons to compare outcomes with other centres.

Site for Healthcare Professionals Only

You are about to access Elios Vision’s online platform for healthcare professionals outside of the United States. This platform is intended to provide general product information for education and illustration purposes. It is not intended to provide information to the general public or medical advice.

As product information, availability, indication, and trade names may vary from country to country, the content of this site may not be fully in-line with the approved or cleared product information in the country you are accessing from. Unless stated otherwise for specific product or event pages, the content on this site is based on the regulatory and legal principles applicable to the United Kingdom.

By closing this popup, I confirm that:

  • I understand that this platform is directed to Healthcare Professionals only and that I am a licensed Healthcare Professional.
  • I have read and agree to Elios Vision’s terms and conditions and privacy policy.